Moonwalk Biosciences Announces $70 Million Series B Funding to Advance RNAi Development
Moonwalk Biosciences has secured $70 million in Series B funding, which will be used to advance its RNA interference (RNAi) therapies. The company's treatments have shown promising results by reducing body weight and fat mass while preserving lean muscle mass. Moonwalk plans for its lead development candidate to enter first-in-human clinical studies by late 2027. The announcement comes amid broader market updates from the NYSE, including a rise in ICE Brent Crude prices above $100 per barrel due to ongoing Middle East tensions and inflation data expected later this week. Additionally, defense company Covenant has emerged from stealth mode with significant funding backing from Andreesen Horowitz and Lightspeed. Moonwalk's CEO, Dr. Alex Aravanis, will discuss the future of its treatments on NYSE Live, highlighting investor interest in biotech innovation.
